NAFDAC alerts Nigerians to counterfeit breast cancer drug Phesgo in Nigeria

Nigeria's healthcare sector faces a critical crossroads as the continent grapples with competing pharmaceutical realities. While the nation celebrates the arrival of lenacapavir—a potentially transformative HIV prevention therapy—regulators simultaneously grapple with an expanding counterfeit drug crisis that threatens both public health and investor confidence in the region's pharmaceutical ecosystem. The National Agency for Food and Drug Administration and Control (NAFDAC) recently issued urgent alerts regarding counterfeit batches of Phesgo, a critical breast cancer therapeutic, circulating across West Africa and beyond. The implicated batch number B2346B16 has been identified in at least four countries, including Nigeria, Turkey, and the Philippines, bearing identical falsified documentation. This coordinated counterfeiting operation underscores the sophistication of pharmaceutical fraud networks operating across African supply chains—a reality that demands immediate attention from both policymakers and investors considering entry into Nigeria's pharmaceutical market. Counterfeit pharmaceuticals represent one of Africa's most insidious economic challenges. The World Health Organization estimates that up to 10 percent of medicines circulating in low- and middle-income African countries are substandard or falsified, disproportionately affecting treatments for cancer, HIV, and other chronic conditions. For Nigerian consumers, the proliferation of fake oncology drugs poses existential risks, while simultaneously eroding trust in the formal healthcare system. European